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EDITORIAL
c-erbB-2 oncogene as a prognostic marker in breast cancer
T.J. Perren
Institute for Cancer Studies, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
During the 1980's much has been learnt about early breast
cancer and several clear guidelines have emerged to assist in
the management of such patients. It is now clear that conser-
vative surgery such as lumpectomy or quadrantectomy
followed by radiotherapy gives the same survival as more
radical surgery (Fisher et al., 1985; Veronesi et al., 1990; Van
de Schueren et al., 1988). Following publication of the recent
overview of adjuvant therapy trials it is also now clear that
adjuvant chemotherapy can significantly prolong the survival
of women younger than 50 years at the time of diagnosis and
that adjuvant tamoxifen has a similar effect in those older
than 50 (Early Breast Cancer Trialists Collaborative Group,
1988).
Axillary nodal status is generally accepted to be the most
important prognostic factor in patients with operable breast
cancer. In the overview 73% of the women in the chemo-
therapy studies and 57% of those in the tamoxifen studies
were node positive. Detailed analyses of outcome amongst
patients with positive and negative axillary nodes are awaited
but, the initial report suggests that although the proportional
reductions in mortality amongst women with and without
axillary nodal involvement appear to be similar, this reduc-
tion in mortality does not achieve conventional statistical
significance for either form of adjuvant treatment in an
analysis restricted to patients with negative axillary nodes.
The prognosis of patients who present with operable breast
cancer is extremely variable and tremendous efforts have
been made over the years to identify additional factors which
may be measured at the time of presentation which will give
an accurate indication as to the likely prognosis of a given
patient, and which may then be used to assist in decision
making regarding the choice of treatment for that patient.
Such work has led to the development of prognostic indices.
In the UK the best known of these indices is that derived in
Nottingham (Haybittle et al., 1982; Todd et al., 1987) which
identified lymph node stage, histological grade of the primary
tumour, and size of the primary tumour as independent
prognostic indicators. The Nottingham index can be used to
divide patients into five separate prognostic groups, the
group with the best prognosis (representing 11% of patients)
had a 5 year survival of 91%, whereas that with the worst
prognosis (10% of the patients) had a 5 year survival of only
17%. Such indices are however not always accurate for the
individual patient and currently they are not being widely
used to select patients for therapy. The Nottingham index
may not be applicable to the general breast cancer popula-
tion because it was derived in a centre where the pathologist
had a special interest in determining histological grade and
where the surgeons performed detailed analysis of both axil-
lary and internal mammary nodal status.
Despite the proven prognostic value of nodal status, a
number of factors have led towards a reduction in axillary
staging including the increasing use of conservative surgery
and perhaps the over-interpretation of results from studies
such as that run by the Nolvadex Adjuvant Trial Organisa-
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tion (1988) which showed the effect of tamoxifen to be
independent of nodal status, menopausal status and hormone
receptor status. Whilst this trend is not to be encouraged, it
represents a real phenomenon perhaps fuelled by a wish to
avoid morbidity such as arm oedema which may be associat-
ed with axillary surgery particularly if combined with radio-
therapy. There is therefore a clear need for the development
of accurate prognostic indices which do not involve axillary
surgery and which will also help to identify the 30% of
patients who still relapse and die within 10 years despite
being pathologically node negative (Craig Henderson et al.,
1989). It would also be extremely useful to be able to reliably
identify the group of patients who relapse and die very
quickly, for whom it may be appropriate to consider more
intensive therapies.
Hunts for new prognostic factors have considered variables
such as oestrogen receptor (ER) status (Fisher et al., 1988) or
the use of flow cytometry to determine ploidy and S-phase
fraction (Clark et al., 1989; Fallenius et al., 1988). Publica-
tion of preliminary papers by Sainsbury et al. (1987) and by
Slamon et al. (1987) showing that patients with over expres-
sion of the epidermal growth factor receptor (EGFR) or
amplification of the c-erbB-2 oncogene had a poor prognosis,
has drawn attention to the evaluation of oncogenes and
growth factors as potential prognostic markers.
The most studied oncogene in breast cancer is c-erbB-2
and papers addressing its biological or clinical significance
from at least 26 different groups can be found in the liter-
ature. This gene which is also known as neu or HER-2 or
HER-2/neu codes for a putative growth factor receptor of the
tyrosine kinase family which is closely related to, but distinct
from EGFR (Coussens et al., 1985). The ligand for the
c-erbB-2 protein is as yet unknown, although two candidate
ligands have recently been identified (Lippman et al., Data
presented at UICC 15th International Cancer Congress,
Hamburg 1990).
In this edition of the British Journal of Cancer, four further
papers concerning the prognostic significance of c-erbB-2
expression are published. Three of these papers are particu-
larly notable: two because they are amongst the largest
systematically collected series in the literature reporting data
on 497 and 462 patients respectively (Lovekin et al., 1991;
Winstanley et al., 1991); the third paper (Gullick et al., 1991)
is notable because it reports the results of a form of meta-
analysis which combines the results of three relatively small
previously published studies (Gusterson et al., 1988; Barnes
et al., 1988; Wright et al., 1989a) to produce a much more
statistically robust conclusion than could be derived from
any one of the studies alone. The fourth papers reports the
results of a moderately sized study (172 patients) and is
interesting because in addition to reporting the association
between c-erbB-2 expression and conventional prognostic fac-
tors it also examines the association of its expression with
S-phase fraction as a marker of tumour proliferation as
measured by DNA flow cytometry (O'Reilly et al., 1991).
All four groups used the polyclonal antiserum 21N as
produced by Gullick et al. (1987), to stain archival formalin
fixed paraffin embedded breast tumours, and all considered
tumours expressing moderate to strong membrane staining to
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be positive for c-erbB-2. The percentage of tumours express-
ing the oncogene was consistently in the upper teens or low
twenties which is entirely consistent with the results of other
published studies using monoclonal or polyclonal antibodies
on formalin fixed paraffin embedded sections (Thor et al.,
1989; Paik et al., 1990; Walker et al., 1989; Van de Vivjer et
al., 1988; Richner et al., 1990).
Much of the previously published data concerns the asso-
ciations between c-erbB-2 expression and conventional
prognostic factors. The results of these studies have varied
considerably but several studies have found consistent results
with respect to certain prognostic factors. The original study
reported by Slamon et al. (1987) showed a positive associa-
tion between c-erbB-2 expression and the number of involved
axillary nodes, this finding has not been generally reproduci-
ble but finds some support in three other studies (Tandon et
al., 1989; Guerin et al., 1989; May et al., 1990) and indirectly
in the study by Zhou et al. (1989) who found c-erbB-2
expression to be significantly higher in stage III/IV tumours
than stage I/II tumours. Similar results with respect to stage
are also described by Borg et al. (1990) in another recently
published paper. None of the presently considered papers
finds any significant relationship between c-erbB-2 expression
and nodal status. However, Lovekin et al. demonstrate an
increasing frequency of c-erbB-2 expression in patients with
more advanced disease: 12.4% of the node negative group
expressed the oncogene compared with 17.4% of the node
positive operable group and 20% of the 180 patients with
stage III or IV tumours. Another staging variable occasion-
ally examined for its association with c-erbB-2 expression is
the size of the primary tumour. Winstanley et al. describe a
significant association between size and c-erbB-2 expression
(P= 0.0054). Similar associations have previously been de-
scribed by van de Vivjer et al. (1988) and Borg et al. (1990)
with P-values of 0.006 and 0.0001 respectively. The marked
variation between groups in associations found to be signi-
ficant is illustrated by the fact that neither Gullick et al. or
O'Reilly et al. were able to find any significant association
between size and c-erbB-2 expression and indeed in the
O'Reilly study the P-value for the association was 0.97.
Other widely investigated associations are those between
c-erbB-2 status and markers of differention including histo-
logical grade, nuclear grade and hormone receptor status.
For the association between c-erbB-2 and histological or
nuclear grade, a form of consistency emerges. Not all studies
show the highly significant positive associations between
grade and c-erbB-2 oncogene expression that were reported
by Garcia et al. (1989), Paik et al. (1990) and Berger et al.
(1988). However, where examined, an association that just
achieves statistical significance is often found (Wright et al.,
1989a; Barnes et al., 1988; Parkes et al., 1990; Walker et al.,
1989) or alternatively there may be a non significant trend in
the same direct (van de Vivjer et al., 1988; Ro et al., 1989).
Three of the four papers published in this edition of the
Journal have considered this association and the results fit
the described pattern: Lovekin et al. describe a highly
significant association (P<0.001) whilst Gullick et al. de-
scribe the same association but with a P-value of only 0.04;
O'Reilly on the other hand describes an association which
fails to achieve statistical significance (P = 0.12). The story is
very similar for hormone receptor status although this has
been less widely evaluated. Papers describing a strong nega-
tive association between c-erbB-2 expression and ER or pro-
gesterone receptor status include those by Borg et al. (1990),
Adnane et al. (1989), Guerin et al. (1989), Tandon et al.(1989); whilst Zeillinger et al. (1989), Berger et al. (1988),
Slamon et al. (1987), Garcia et al. (1989) and May et al.(1990) all describe a weaker negative association. Of the
papers considered in this editorial only Lovekin et al. de-
scribe a strong negative association between c-erbB-2 expres-
sion and ER status (P <0.003) and this is confined to the
subset of 180 patients, with stage III or IV breast cancer, no
significant relationship having been seen in the group of 497
patients with operable disease.
There has been relatively little investigation of the relation-
ship between c-erbB-2 expression and other markers of differ-
entiation. Ploidy has previously been investigated by two
groups neither of whom found any significant association
(Tavassoli et al., 1989; Ro et al., 1989) although in the paper
by Ro et al. (1989) there was a non significant trend towards
an increased incidence of c-erbB-2 expression in aneuploid
tumours (27% vs 14% - P = 0.19). O'Reilly et al. (1991)
describe a similar association with 20% of aneuploid
tumours expressing c-erbB-2 compared to only 9% diploid
tumours (P = 0.1). The same authors have also extended
their investigation to include not only ploidy but also S-
phase fraction, and have found, in a chi-squared analysis,
that c-erbB-2 expression was significantly higher in those
tumours with an S-phase fraction above the median (25% vs
6% - P = 0.003). The correlation coefficient for the above
association was, however, only 0.18 indicating that this
association was weak with, less than 5% of the variability in
S-phase fraction being due to it's association with c-erbB-2.
Bacus et al. (1990) have performed a more detailed analysis
of this association using the Feulgen DNA staining method
to evaluate the DNA content of cells which were simultan-
eously stained for c-erbB-2 using a polyclonal antiserum.
Forty-five cases were examined; interestingly the level of
c-erbB-2 positivity was rather higher at 49% which might be
partly explained by the inclusion of five cases of ductal
carcinoma in situ and of other tumours with an extensive
intraduct component. All 22 tumours positive for c-erbB-2
were found to have a near tetraploid DNA content with a
mean DNA index of 1.9 ± 0.19 whilst the DNA content of
tumours negative for c-erbB-2 varied from diploid to three
times the normal DNA content with a mean DNA index of
1.4 (± 0.58).
The all-important relationship between c-erbB-2 expression
and prognosis has been extremely widely investigated with
differing results. One problem with the interpretation of such
studies is that the characteristics of the patients included
varies considerably. Some studies include only patients with
operable early stage breast cancer, whilst others also include
patients with stage III and IV disease. Some studies restrict
their analyses to node positive and others to node negative
patients. Most studies present survival data, but not all of
these also present recurrence data.
Much of the initial interest in c-erbB-2 as a prognostic
marker was generated by work of Slamon et al. (1987) which
showed that in 86 node positive patients survival was signi-
ficantly worse for those patients whose tumours were c-erbB-
2 positive; similar results were also seen with respect to
recurrence. Multivariate analysis of these data showed the
independent prognosticators for survival to be the number of
positive nodes, c-erbB-2 status, and ER status. These data
were subsequently confirmed in a larger study from the same
group (Slamon et al., 1989) which included 526 patients, of
whom 345 were node positive. No data are given for the
association between c-erbB-2 expression and outcome for the
group as a whole but in the node positive subset there was an
association between c-erbB-2 expression and poor prognosis
in terms of recurrence (P = 0.01) and survival (P = 0.041). In
multivariate analysis c-erbB-2 expression retained its prog-
nostic significance being second only to the number of axil-
lary nodes in both the disease free and overall survival
analysis. In the node negative subset however there was no
association between c-erbB-2 expression and either recurrence
or survival.
At least 20 other groups have now published data concern-
ing the prognostic significance of c-erbB-2, of these only four
groups have failed to find a prognostic effect of c-erbB-2 in at
least one sub group (Zhou et al., 1989; Ali et al., 1988;
Gusterson et al., 1988; Barnes et al., 1988). Van de Vivjer et
al. (1988) found an effect of borderline statistical significance
on a survival but not on a recurrence free survival analysis,
this effect disappeared on multivariate analysis and it was
concluded that c-erbB-2 status was of limited prognostic
value. On the other hand four groups have been able to show
an overall prognostic effect of c-erbB-2 in both recurrence
free and survival analyses (Wright et al., 1989a; Paik et al.,
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1990; Walker et al., 1989; Tsuda et al., 1989). All of these
papers show that the prognostic effect of c-erbB-2 is main-
tained in multivariate analysis. If the details of those studies
which show no, or only a limited, prognostic effect of c-erbB-
2 are compared to those where there is an overall prognostic
effect it is apparent that significant prognostic effects tend to
be seen in the larger studies. This is borne out by the result
of the studies published in this edition of the Journal three of
which showed an overall effect of c-erbB-2 on prognosis and
all of these studies contained more than 450 patients.
Of the papers published in this edition of the Journal, only
that from Gullick et al. shows a significant overall associa-
tion between c-erbB-2 expression and both recurrence and
survival which is confirmed in multivariate anlaysis. This
paper lends further support to the hypothesis that some of
the apparent differences in the prognostic significance of
c-erbB-2 expression between groups may simply be a function
of study size. In their overview they include two studies
which individually showed no significant prognostic effect of
c-erbB-2 expression, although both showed a non significant
trend towards poor prognosis for patients with tumours
positive for c-erbB-2 (Gusterson et al., 1988; Barnes et al.,
1988). However, when considered together with a third study,
which had individually shown an independent prognostic
effect in terms of both relapse and survival (Wright et al.,
1989a) the strong independent prognostic effect for the group
as a whole was confirmed and shown to be equivalent in
both node positive and node negative patients.
Of the other two large studies published in this edition of
the Journal, both restrict their analyses to survival and both
report a highly significant association between c-erbB-2 ex-
pression and poor survival. In the Lovekin paper c-erbB-2 is
found not to be an independent prognostic indicator in a
model which also considers axillary nodal stage, size of
primary tumour, and histological grade. However, in this
study there was a very strong association between c-erbB-2
status and grade and when grade was omitted from the
multivariate analysis c-erbB-2 status became an independent
prognosticator. In the Winstanley paper multivariate analysis
showed c-erbB-2 receptor status to be an independent prog-
nosticator alongside axillary nodal status and primary
tumour size, the effect of histological grade was however not
tested in this study.
Other studies have shown a significant effect of c-erbB-2
expression in the overall survival analysis but not in the
recurrence free analysis (Paik et al., 1990; Parkes et al., 1990;
Van de Vivjer et al., 1988), but only that by Paik shows
c-erbB-2 expression to be independent prognostic significance
on multivariate analysis.
Most groups have examined the prognostic significance of
c-erbB-2 expression in sub-groups defined by conventional
prognostic indicators. The results are again conflicting. Some
papers find the prognostic effect of c-erbB-2 expression to be
restricted to the node positive subset (Slamon et al., 1989;
Tandon et al., 1989; Borg et al., 1990) and similar results are
described by O'Reilly et al. who, however, show that the
independent prognostic effect of c-erbB-2 expression was
restricted to the recurrence free survival analysis. Other
groups have made the potentially very important observation
that there is a significant prognostic effect of c-erbB-2 expres-
sion in groups that would generally be considered to have a
good prognosis. This includes the node negative subset where
an association between c-erbB-2 expression and poor survival
is described in papers by Wright et al. (1989a) and Ro et al.
(1989). Paik et al. (1990) demonstrated that the maximum
prognostic effect of c-erbB-2 expression, in terms of survival,
was seen in those patients who had well differentiated
tumours, particularly in those who were also node negative.
A similar effect was noted in a study of 79 node negative
patients (Richner et al., 1990) where although there was no
overall association between c-erbB-2 expression and overall
survival, such an association was found in the ER positive
subset (P = 0.001). Wright et al. (1989a) also found that the
prognostic effect of c-erbB-2 expression was stronger in ER
positive than ER negative tumours and also stronger in
EGFR negative tumours than EGFR positive tumours. May
et al. (1989) have shown that it is possible to define a group
of ER positive patients who have a poor prognosis. These
patients, termed ER+(R2), have a ratio of ER protein to, ER
mRNA of greater than 1.5. These authors have recently
extended this work (May et al., 1990) and shown that in a
multivariate analysis, c-erbB-2 expression is independent of
ER+(R) status and is therefore capable of defining groups
with a higher risk of relapse from within both the ER+(R1)
and ER+(R2) groups, as well as from within the ER negative
group where the effect was particularly strong.
Of the four papers published in this edition of the Journal
Gullick et al. show clearly that the prognostic effect of
c-erbB-2 receptor expression is equivalent in node positive
and in node negative patients and make the extremely impor-
tant point that in order to reliably demonstrate the prognos-
tic effect of c-erbB-2 expression in the node negative subset
large numbers of patients are required. This is because
c-erbB-2 is expressed relatively infrequently and because node
negative patients have a much better prognosis than node
positive patients and therefore relapse and die less frequently.
Many more node negative cases are therefore required to
obtain similar statistical significance because statistical power
is dependent upon the number of events in the study.
It is not clear how c-erbB-2 expression exerts its prognostic
effect and is may be simply that tumour cells positive for
c-erbB-2 have a growth advantage over cells negative for this
oncogene. There may however also be some relationship
between c-erbB-2 expression and responsiveness to treatment.
A number of studies show that the prognostic effect of
c-erbB-2 expression is stronger for survival than it is for
recurrence (O'Reilly et al., 1991; Gullick et al., 1991; Wright
et al., 1989a; Paik et al., 1990; Ro et al., 1989; Parkes et al.,
1990; Tsuda et al., 1989; Van de Vivjer et al., 1988). This
implies that part of the prognostic effect of c-erbB-2 expres-
sion is exerted during the period after recurrence, a period
when the patients are likely to be receiving chemo- or hor-
monal therapy. Some preliminary results published in ab-
stract form lend some support to this hypothesis. Fifty-nine
patients with operable breast cancer who relapsed after
primary surgical management alone were all treated with
tamoxifen, 19 patients responded, 18 of whom (95%) had
tumours that were negative for c-erbB-2; of the non respon-
ders, only 28 of the 40 (70%) were negative for c-erbB-2
(P<0.07). The 13 patients who were positive for c-erbB-2
had a particularly poor prognosis and 12 (92%) showed
evidence of disease progression within 6 months of starting
tamoxifen compared to only 31 of 46 (67%) who were
negative for c-erbB-2, post relapse survival was also signi-
ficantly shorter for this group of patients (P<0.01) (Wright
et al., 1989b).
In summary, c-erbB-2 expression appears to be a useful
addition to the prognostic armamentarium. There is evidence
to suggest that its expression is more frequent in tumours of
advanced stage and in tumours that are more poorly differ-
entiated. These associations are however far from absolute as
is shown by the marked difference in results between pub-
lished papers. Because the oncogene is expressed relatively
infrequently, larger studies such as those published in this
edition of the Journal are required to clearly demonstrate its
prognostic significance, and this is particularly the case when
subset analyses are performed looking at those groups which
would be considered to have a good prognosis by conven-
tional prognostic indicators.
One major limitation of the studies published to date is
that they are all retrospective and the patients included are
therefore limited by the availability of material and the
analyses limited by the availability of information regarding
other prognosticators. Large prospective studies are now re-
quired to fully assess the prognostic significance of this inter-
esting new biological variable. Such studies should also be
able to provide information as the whether c-erbB-2 expres-
sion can predict responsiveness to chemo- or hormonal-ther-
apy. Further work is also required to assess the relative
strength of c-erbB-2 as a prognostic marker relative to other
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promising new markers such as the proteases Cathepsin D
(Spyratos et al., 1989; Thorpe et al., 1989; Tandon et al.,
1990) and urokinase type plasminogen activator antigen
(Janicke et al., 1989) as well as other markers such as the
NM23 gene (Bevilacqua et al., 1989) and mutant p53 (Harris
et al., 1990).
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